Pancarcinoma Antigen

Mouse IgG2a

UCLA-P3 cells

KS1/4 antigen (Ag), defined by the KS1/4 antibody (KS1/4), is expressed in many epithelial-derived carcinomas and normal epithelial cell surfaces. The cDNA encoding KS1/4 has been isolated and contains an open reading frame of 314 amino acids including a putative signal sequence. KS1/4 Ag migrates as three glycosylated polypeptides with molecular masses of 35, 40 and 42 kDa.  The 40 and 42 kDa species are similar proteins and appear to differ only by their degree of N-linked glycosylation. The 35 kDa species results from proteolytic cleavages of the larger molecular weight proteins. KS1/4 was first described as a monoclonal antibody which recognized a lung adenocarcinoma associated antigen.  In oncolytic drug targeting studies, KS1/4 suppressed the growth of human lung tumor xenografts in athymic nude mice. Subsequent studies showed that KS1/4 reacts with a variety of tumor tissues including colon, breast, ovarian, and pancreas. It also recognizes normal epithelium including colon, stomach, small intestine, liver, kidney, lung, pancreas, skin and ovary. These results suggest that KS1/4 Ag represents an epithelial cell/epithelial-derived carcinoma marker. KS1/4 recognizes a 40 - 42 kDa antigen expressed on the cell surfaces of a variety of epithelial tumors and normal epithelial cell types.   KS1/4 also recognizes a 35 kDa proteolytic fragment.   UCLA-P3 cells derived from a human adenocarcinoma of the lung were used as immunogen.

KS1/4 KS1/4 antigen (Ag), defined by the KS1/4 antibody (KS1/4), is expressed in many epithelial-derived carcinomas and normal epithelial cell surfaces. The cDNA encoding KS1/4 has been isolated and contains an open reading frame of 314 amino acids including a putative signal sequence. KS1/4 Ag migrates as three glycosylated polypeptides with molecular masses of 35, 40 and 42 kDa.  The 40 and 42 kDa species are similar proteins and appear to differ only by their degree of N-linked glycosylation. The 35 kDa species results from proteolytic cleavages of the larger molecular weight proteins. KS1/4 was first described as a monoclonal antibody which recognized a lung adenocarcinoma associated antigen.  In oncolytic drug targeting studies, KS1/4 suppressed the growth of human lung tumor xenografts in athymic nude mice. Subsequent studies showed that KS1/4 reacts with a variety of tumor tissues including colon, breast, ovarian, and pancreas. It also recognizes normal epithelium including colon, stomach, small intestine, liver, kidney, lung, pancreas, skin and ovary. These results suggest that KS1/4 Ag represents an epithelial cell/epithelial-derived carcinoma marker. KS1/4 recognizes a 40 - 42 kDa antigen expressed on the cell surfaces of a variety of epithelial tumors and normal epithelial cell types. KS1/4 also recognizes a 35 kDa proteolytic fragment. UCLA-P3 cells derived from a human adenocarcinoma of the lung were used as immunogen.

Mouse IgG2a

克隆 KS1/4 (RUO)

0.5 mg/ml

Flow cytometry (Routinely Tested), Immunofluorescence, Immunohistochemistry-frozen, Immunoprecipitation (Reported)

Human (QC Testing)

Pancarcinoma Antigen

Aqueous buffered solution containing ≤0.09% sodium azide.

研发参考(5) 1. Bumol TF, Marder P, DeHerdt SV, Borowitz MJ, Apelgren LD. Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody. Hybridoma. 1988; 7(4):407-415. (Clone-specific: Flow cytometry, Immunohistochemistry). 2. Perez MS, Walker LE. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker. J Immunol. 1989; 142(10):3662-3667. (Clone-specific: Immunoprecipitation). 3. Spearman ME, Goodwin RM, Apelgren LD, Bumol TF. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J Pharmacol Exp Ther. 1987; 241(2):695-703. (Biology). 4. Varki NM, Reisfeld RA, Walker LE. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res. 1984; 44(2):681-687. (Immunogen: Immunofluorescence, Immunohistochemistry, Immunoprecipitation). 5. Varki NM, Reisfeld RA, Walker LE. Effect of monoclonal antibody-drug conjugates in teh in vivody growth of h uman tumors established in nude mice. In: Reisfeld R, Sell S, ed. Monoclonal Antibodies in Cancer Therapy, vol. 27. New York: Alan R Liss, Inc; 195:207.